Novo Nordisk logo view in the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024.
Tom Little Reuters
Actions Novo Nordisk He jumped on Friday after the Danish pharmaceutical giant reported positive results at an early stage for his once weekly obese obesity.
The study showed that the treatment, which is administered by injection, caused an average reduction in a weight of 22% in obese patients and overweight after 36 weeks.
The actions were recently at 9.2% at 11:22 in London.
Amykretin is focused on the same intestinal hormone that imitates Wegova, known as GLP-1, as well as a pancreatic hormone called Amylin, which affects hunger. Wegova is the flagship drug of Novo Nordisk obesity, while ozempic is the treatment of diabetes.
Novo said that the most undesirable effects of amicretin processing were the digestive tract, with the vast majority “mild to moderate in terms of heaviness”.
“We are very much encouraged by the results of the subcutaneous phase 1b/2a for the body of migraitin in overweight or obesity people,” said Martin Lange, Vice President of Development at Novo Nordisk in a statement.
“The results visible in the study confirm the potential for lowering the body weight of this innovative agonist of the GLP-1 GLP-1 receptor and amicretin, which we have previously seen in the case of an oral formula.”
Novo also develops an obese pill of obese, which Tests at an early stage The announced in September led to an average weight loss of 13.1% after 12 weeks.
This is a developing story. Check updates.